MDT

87.56

+0.44%↑

A

114.42

-2.15%↓

VEEV

160

-7.43%↓

HQY

83.34

+1.87%↑

TLRY

6.65

-1.92%↓

MDT

87.56

+0.44%↑

A

114.42

-2.15%↓

VEEV

160

-7.43%↓

HQY

83.34

+1.87%↑

TLRY

6.65

-1.92%↓

MDT

87.56

+0.44%↑

A

114.42

-2.15%↓

VEEV

160

-7.43%↓

HQY

83.34

+1.87%↑

TLRY

6.65

-1.92%↓

MDT

87.56

+0.44%↑

A

114.42

-2.15%↓

VEEV

160

-7.43%↓

HQY

83.34

+1.87%↑

TLRY

6.65

-1.92%↓

MDT

87.56

+0.44%↑

A

114.42

-2.15%↓

VEEV

160

-7.43%↓

HQY

83.34

+1.87%↑

TLRY

6.65

-1.92%↓

Начало・Списък с акции・Pliant Therapeutics Inc

Search

Pliant Therapeutics Inc

Затворен

1.35 3.85

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.31

Максимум

1.35

Ключови измерители
By Trading Economics
Приходи	2.7M -24M
EPS	-0.354
Служители	49
EBITDA	-5.3M -28M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+103.82% upside

Дивиденти
By Dow Jones
Следващи печалби	7.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-5K 81M
Предишно отваряне	-2.5
Предишно затваряне	1.35

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.43 / 1.6 Подкрепа & съпротива

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.04.2026 г., 20:44 ч. UTC

Печалби

Costco Reports 11% Growth in March Sales

8.04.2026 г., 23:51 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

8.04.2026 г., 23:51 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Talks to End Iran War -- Market Talk

8.04.2026 г., 23:36 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Lower on Likely Technical Correction -- Market Talk

8.04.2026 г., 22:56 ч. UTC

Пазарно говорене

Ramelius Resources May Downgrade Cost Guidance This Month -- Market Talk

8.04.2026 г., 22:45 ч. UTC

Пазарно говорене

Constellation Brands Points to Continuing Challenges Among Hispanic Consumers -- Market Talk

8.04.2026 г., 22:17 ч. UTC

Пазарно говорене

Applied Digital Says Its Holding Out for Quality Customers -- Market Talk

8.04.2026 г., 21:52 ч. UTC

Значими събития в новините

A Closer Look at Iran's 10 Demands -- and Which the U.S. Might Accept -- Update

8.04.2026 г., 21:24 ч. UTC

Печалби

FedEx Freight Aims for 12% Profit Growth. How That Compares to the Leader. -- Barrons.com

8.04.2026 г., 21:01 ч. UTC

Значими събития в новините

Oil Prices Tumble Despite Conflicting Reports About the Strait of Hormuz -- Barrons.com

8.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

8.04.2026 г., 20:43 ч. UTC

Придобивния, сливания и поглъщания

Oracle Is Expressing No Opinion and Is Neutral as to Whether Stockholders Should Tender Their Shrs in Response to TRC's Offer >ORCL

8.04.2026 г., 20:43 ч. UTC

Придобивния, сливания и поглъщания

Oracle Does Not Endorse TRC's Mini-Tender Offer or the Offer Documentation >ORCL

8.04.2026 г., 20:43 ч. UTC

Придобивния, сливания и поглъщания

Oracle: Offer Represents Less Than 0.04% of Outstanding Common Stk >ORCL

8.04.2026 г., 20:42 ч. UTC

Придобивния, сливания и поглъщания

Oracle: TRC Offer Is to Purchase Up to 1M Shrs of Common Stk at $140.50/Shr in Cash >ORCL

8.04.2026 г., 20:42 ч. UTC

Придобивния, сливания и поглъщания

Oracle Received Notice of Unsolicited Mini-Tender Offer by TRC Dated March 24 >ORCL

8.04.2026 г., 20:42 ч. UTC

Придобивния, сливания и поглъщания

Oracle Responds to TRC Cap Mini-Tender Offer

8.04.2026 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

8.04.2026 г., 20:11 ч. UTC

Придобивния, сливания и поглъщания

Intel Corp.: Repurchased 49% Equity Interest in JV Related to Intel's Fab 34 in Ireland >INTC

8.04.2026 г., 20:11 ч. UTC

Придобивния, сливания и поглъщания

Intel Corp.: $14.2B Repurchase Price Financed with Cash on Hand and a Bridge Loan of $6.5B >INTC

8.04.2026 г., 20:11 ч. UTC

Придобивния, сливания и поглъщания

Intel Corp.: Repurchased JV Stake From Apollo-Managed Funds and Affiliates >INTC

8.04.2026 г., 19:44 ч. UTC

Печалби

These Companies Pay 5% Dividend Yields, and They're Hiking Them Too -- Barrons.com

8.04.2026 г., 19:16 ч. UTC

Пазарно говорене

Hogs Follow Cutout Prices Lower -- Market Talk

8.04.2026 г., 19:02 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

8.04.2026 г., 19:02 ч. UTC

Пазарно говорене

Oil Futures Plunge as Cease-Fire Raises Hopes for Restored Supply -- Market Talk

8.04.2026 г., 18:58 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Fall in Line With Slump in Oil -- Market Talk

8.04.2026 г., 18:51 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

8.04.2026 г., 18:51 ч. UTC

Пазарно говорене

Levi Strauss CEO Says Expanded Offerings, DTC Focus Are Working -- Market Talk

8.04.2026 г., 18:14 ч. UTC

Значими събития в новините

Fed Minutes Suggest a Lengthy Iran War Could Lead to Rate Hikes -- Barrons.com

8.04.2026 г., 18:05 ч. UTC

Значими събития в новините

Oil Prices Continue to Tumble After Cease-Fire Despite Slow Reopening of Strait of Hormuz -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Ценова цел

By TipRanks

103.82% нагоре

12-месечна прогноза

Среден 2.67 USD 103.82%

Висок 3 USD

Нисък 2 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Pliant Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

2

Купи

3

Задържане

0

Продай

Според 5 анализатори, дали борсови рейтинги на Pliant Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.43 / 1.6Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Други акции от сектора

MDT

Medtronic PLC

87.56

A

Agilent Technologies Inc

114.42

VEEV

Veeva Systems Inc

160

HQY

HealthEquity Inc

83.34

TLRY

Tilray Brands Inc

6.65

Live chat